SCN PARTICIPATES IN RESEARCH CONSORTIUM GRANTED EUR 2.2 MILLION BY DANISH RESEARCH COUNCIL

Scandinavian Clinical Nutrition (SCN) participates in a Danish innovation consortium which aims to develop models for faster development of effective and safe nutraceuticals in accordance with FDA’s new concept ”Quality by Design”.

The Danish state’s research council for technology and innovation has granted DKK 16.8 million to a three-year collaboration project called “Prediction of Drug Absorption”, which aims to develop more efficient methods for developing safe and effective nutraceuticals. The project embodies two research groups at the University of Copenhagen and six companies, of which Bioneer-Farma, AstraZeneca and SCN are three examples.

The project is coordinated by Bioneer-Farma, which is a collaboration between Bioneer A/S and the University of Copenhagen with the objective to develop technological services within the pharmaceutical field. The project is managed in accordance with the American FDA’s concept Quality by Design, and the objective is to develop a platform with different models for digestion and absorption in the mouth and the intestines, making it easier for researchers to see how and how fast different substances are absorbed by the body. The models can also be used to develop safe and effective products (formulations), and to speed up the development and registration processes with relevant authorities.

The project is of great importance to SCN since many ingredients (nutrients, nutraceuticals and herbal extracts) which are used to make dietary supplements and natural remedies often have an unsatisfactory and/or unexplored bioavailability (a measurement of the body’s ability to absorb the substance). Better knowledge about this will lead to better products, and SCN sees great potential in the project and the research field.

“The fact that SCN is a part of a collaboration of this kind is an important step in our strategy to develop scientifically documented dietary supplements and natural remedies together with leading researchers and universities”, says Dan Edwall, VP R&D at SCN. “We are also very glad that the project lifts the perspective from the underlying research and sees the whole path to the consumer, via registration by authorities and other instances, so that the market can gain access to new and better products without unnecessary delays”.

For more information, please contact:

Anders Struksnes, Senior Vice President SCN, as@scnutrition.com, +47 911 98 942

Dan Edwall, VP R&D SCN, de@scnutrition.com, +46 707 98 80 89

Lars Lindmark, projektansvarig, lars.lindmark@telia.com, +46 701 47 21 45

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).